Uncertainty remains regarding optimal antithrombotic treatment of patients with atrial fibrillation presenting with myocardial infarction or undergoing coronary intervention. Present expert statements (Level C evidence) recommend triple therapy with aspirin, clopidogrel, and vitamin K antagonist, with treatment limited to as short a time as possible because of a perceived greater risk of bleeding with prolonged treatment. In the current study, we examined the risk of bleeding associated with different antithrombotic treatment regimens in a nationwide real-life cohort of patients with atrial fibrillation and myocardial infarction and/or coronary intervention. We demonstrated an immediately high risk of bleeding with triple therapy that decreases over time. Nevertheless, the risk was continually elevated in comparison with less intense antithrombotic regimens, which suggests that triple therapy has no safe therapeutic window. No benefit was present for a combined thromboembolic end point of cardiovascular death, myocardial infarction, and ischemic stroke for triple therapy relative to vitamin K antagonist plus a single antiplatelet agent. Until data from randomized trials are available, our results suggest that triple therapy should only be prescribed after careful evaluation of bleeding risk. See p 1185.
Dissociation of Structural and Functional Phenotypes in Cardiac Myosin-Binding Protein C Conditional Knockout Mice
Mutations in the gene encoding cardiac myosin-binding protein-C (cMyBP-C) are common causes of familial hypertrophic cardiomyopathy (HCM) and can also lead to HCM-associated dilation. This primary disease of the myocardium affects a wide range of patient age groups, accounts for the majority of cardiac genetic diseases, and leads to significant morbidity and mortality associated with the development of heart failure, ventricular and atrial arrhythmias, myocardial infarction, and sudden cardiac death. Nevertheless, little is known regarding the mechanisms underlying the development of cMyBP-C-associated HCM, although deficiencies in cMyBP-C are thought to contribute to the pathogenesis of this disease in many cases. Herein, we investigate the onset, progression, and saturation of structural and functional phenotypes caused by the removal of cMyBP-C and assess whether loss of cMyBP-C per se is sufficient to cause the development of HCM-associated dilation. Using adult cMyBP-C conditional knockout mice, we show that acute loss of cMyBP-C affects the duration of cardiac systole and diastole and contributes to the development of diastolic dysfunction, all of which occurs before the onset of cardiac hypertrophy. Moreover, we show that near-complete ablation of cMyBP-C is insufficient to cause HCM-associated dilation in adult mice, whereas the imposition of additional stresses such as increased afterload is sufficient to recapitulate the phenotype. These results help define the gradual changes that precede and progress with the clinical expression of cMyBP-C-associated cardiomyopathy and identify potential avenues in which to prevent, delay, or reverse the progression of this disease. See p 1194.
Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality
Extracellular matrix expansion may be ubiquitous in chronically diseased viable myocardium as shown by histopathologic studies in humans and animals. It is associated with mechanical, vasomotor, and electrical dysfunction and is treatable, but the relationship with outcomes has remained poorly understood. Historically, there has not been a robust noninvasive method to quantify the extent of extracellular matrix expansion in myocardium, which is often diffuse and not detectable by conventional late gadolinium enhancement imaging. Thus, the presence and extent of extracellular matrix expansion has mostly been invisible to clinicians. We employed novel cardiovascular magnetic resonance techniques to quantify extracellular matrix expansion by measuring the extracellular volume fraction in myocardium without myocardial infarction in a consecutive cohort of individuals referred for cardiovascular magnetic resonance. These techniques require: i) robust blood pool and myocardial T1 measurement before and after gadolinium contrast, and ii) hematocrit measurement. Extracellular volume fraction measures of the interstitial space can be embedded in clinical protocols easily and correlate highly with the collagen volume fraction in viable myocardium in most settings. In our study, extracellular matrix expansion appeared prevalent, and the extracellular volume fraction predicted both mortality and the composite endpoint of death/cardiac transplant/left ventricular assist device implantation even after adjusting for age, ejection fraction and myocardial infarction size. The apparent statistical independence of the extracellular volume fraction measure suggests a potential to improve risk stratification in patients. Further work is needed to advance our understanding of the causes, consequences, and treatment of extracellular matrix expansion and myocardial fibrosis. See p 1206.
Prognostic Value of High-Dose Dipyridamole Stress Myocardial Contrast Perfusion Echocardiography
Dipyridamole real-time contrast echocardiography (DipRCE) has considerable advantages over other imaging stress-tests, including no irradiation, spatial and temporal resolution, short test duration, immediate availability of results at the bedside, and the ability to perform stress and rest images in the same setting. The addition of myocardial perfusion (MP) imaging over standard wall motion (WM) analysis during DipRCE improves the sensitivity to detect coronary artery disease (CAD), but its risk reclassification potential to predict hard cardiac events in large numbers of patients with known or suspected CAD remains unknown. We studied 1252 patients with DipRCE and followed them for a median of 25 months. A total of 59 hard events (4.7%) occurred during the follow up (24 deaths, 35 myocardial infarctions). Reversible MP defects added incremental prognostic value and risk reclassification benefit to predict hard events, after adjustment for clinical data, ejection fraction, and WM analysis. A normal MP response during DipRCE identified a low-risk patient group (close to 1% yearly hard event rate) with a better outcome than patients with a normal WM but abnormal MP response. An ischemic WM response, which was always accompanied by MP defects, predicted the highest risk of hard events. Patients with a normal MP response can be reassured regarding their low risk of future 1 or 2-year hard events, regardless of their clinical risk factors or previous CAD history. MP 
Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET)
Several recent randomized trials comparing everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, and no trial was powered for evaluating target-lesion revascularization. Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial is a prospective multicenter randomized, open-label trial comparing EES with SES in Japan. The trial was powered for evaluating noninferiority of EES relative to SES in terms of target-lesion revascularization. From February and July 2010, 3197 patients were randomly assigned to receive either EES (1597 patients) or SES (1600 patients). At 1 year, the primary efficacy end point of target-lesion revascularization occurred in 65 patients (4.3%) in the EES group, and in 76 patients (5.0%) in the SES group, demonstrating noninferiority of EES to SES (P noninferiorityϽ0.0001, and P superiority ϭ0.34). Cumulative incidence of definite stent thrombosis was low and similar between the 2 groups (0.32% versus 0.38%; Pϭ0.77). One-year clinical and angiographic outcome after EES implantation was noninferior to and not different from that after SES implantation in a stable coronary artery disease population with relatively less complex coronary anatomy. Oneyear clinical outcome after both EES and SES use was excellent with a low rate of target-lesion revascularization and a very low rate of stent thrombosis. Clinical follow-up will be continued up to 3 years. Future studies comparing different drug-eluting stents should focus more on patients with complex coronary artery disease to discern meaningful differences in safety and efficacy outcomes. See p 1225.
Outcomes of Restrictive Cardiomyopathy in Childhood and the Influence of Phenotype: A Report From the Pediatric Cardiomyopathy Registry
Restrictive cardiomyopathy is a rare form of cardiomyopathy in childhood with a few risk factors identified for death or transplantation. This analysis from the Pediatric Cardiomyopathy Registry identified 152 cases of restrictive cardiomyopathy among 3375 children with cardiomyopathy (4.5%), approximately one-third of whom had a mixed restrictive/hypertrophic phenotype. Survival did not differ between those with pure and mixed phenotypes, but transplant-free survival was inferior in the pure restrictive cardiomyopathy group. Overall outcomes were worse than for all other forms of cardiomyopathy in the Pediatric Cardiomyopathy Registry. Clinical and echocardiographic risk factors at presentation for worse outcome were identified and should aid the clinician in risk stratification. See p 1237.
Cerebral Embolization During Transcatheter Aortic Valve Implantation: A Transcranial Doppler Study
Neurological events are currently considered one of the most pressing concerns with transcatheter aortic valve implantation (TAVI). A nearly 4-fold risk of such events within 30 days after the procedure was observed for nonoperable patients undergoing TAVI compared with patients treated with optimal medical therapy in cohort B of the Placement of AoRtic TraNscathetER valves (PART-NER) trial, and similar results were found when TAVI was compared with surgical aortic valve replacement in the high-risk population of cohort A. Moreover, a high load of clinically silent embolic lesions was documented on postprocedural cerebral diffusionweighted magnetic resonance imaging, which has raised additional safety concerns. In the present study, serial transcranial Doppler monitoring was performed to elucidate the main source of procedural emboli. During TAVI, high-intensity transient signals were detected in all patients as a surrogate for microembolization. They predominantly occurred during manipulation of the calcified native valve while positioning and implanting the stent valves, with no differences between the transfemoral and the transapical approach and only a trend toward a higher amount of high-intensity transient signals for the self-expandable prosthesis. Despite the omnipresence of high-intensity transient signals, however, only 2 (2.4%) neurological complications occurred within 30 days, and there were no late neurological events. However, these findings corroborate the importance of periprocedural embolization during TAVI and reinforce current calls for an increased focus on this issue, especially when TAVI indications are broadened toward younger, lower-risk patients. Future research is essential to better determine the "real" neurological risk of the TAVI procedure and to thoroughly investigate the feasibility, safety, and efficacy of upcoming strategies to reduce the risk for cerebral embolization, eg, use of less traumatic devices, omission of preparatory valvuloplasty, carotid compression during valve manipulation, or use of active cerebral protection devices. See p 1245.
Cytokine Therapy With Interleukin-2/Anti-Interleukin-2 Monoclonal Antibody Complexes Expands CD4؉CD25؉Foxp3؉ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis
Atherosclerosis is a multifactorial inflammatory disease characterized by the accumulation of lipids and innate and adaptive immune cells, leukocytes, and lymphocytes. Activated lymphocytes are believed to be essential for both the development and exacerbation of atherosclerosis. One way to prevent their activation is to increase regulatory T cells, cells that can control both innate and adaptive immune responses. Regulatory T cells, defined by expression of CD4, CD25, and a transcription factor Foxp3, are mostly thymus derived and account for 5% to 10% of the circulating CD4ϩ T cell population. The cytokine interleukin-2 can stimulate their expansion but is not selective. In this article we present a novel way to chronically expand this T cell population, by complexing the cytokine interleukin-2 with an interleukin-2-neutralizing antibody, which prolongs its duration of action and specifically targets regulatory T cells, markedly increasing their numbers. Other interleukin-2-responsive lymphocytes that can accelerate atherosclerosis do not respond to this cytokine-antibody complex. Treatment with this cytokine-antibody complex inhibits the activation and proliferation of proatherogenic T cells and markedly attenuates development and progression of already developed atherosclerosis. From a clinical perspective, this finding is important because it demonstrates that by specifically targeting cells that can protect against atherosclerosis, in this case pharmacologically expanding regulatory T cell numbers, it is possible to suppress inflammation associated with atherosclerosis as well as attenuate progression of disease. See p 1256.
